According to a long-term follow-up study (7 years) that examined the relationship between NPTX2 levels and MCI onset, however, NPTX2 and AD biomarker changes in CSF Aβ42/Aβ40, p-tau181, or t-tau are independently associated with clinical progression [19]. The gene discussed is NPTX2; the disease is Alzheimer disease.